NCT02480946 - Safety and Tolerability Study of MBS2320 in Healthy Subjects and Subjects With Rheumatoid Arthritis | Biotech Hunter

Enrollment

105

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

March 31, 2017

Study Completion Date

March 31, 2017

Conditions

Arthritis, Rheumatoid

Interventions

DRUG

MBS2320

As described in the arm descriptions

DRUG

Placebo

As described in the arm descriptions

DRUG

Methotrexate

Background therapy as described in the arm descriptions

Trial Locations (3)

Covance Royal Liverpool Clinical Research Unit,Royal Liverpool University Hospital, Liverpool

Covance Clinical Research Unit Ltd., Leeds

NIHR/Wellcome Trust Imperial Clinical Research Facility (CRF), London